U.S. Chemicals Stock News

Abercrombie & Fitch (ANF) opened Q1 2027 with revenue of US$1.1b and basic EPS of US$1.49, alongside net income of US$67.1m for the quarter. The company recorded quarterly revenue of US$1.10b in Q1 2026 and US$1.11b in Q1 2027, while basic EPS moved from US$1.63 to US$1.49 over the same period. This presents a picture in which investors are weighing solid top line scale against more mixed per share outcomes. With trailing net margin coming in lower than the prior year in the provided data,...

Earlier this week, Jabil was part of a broader move in U.S. equities as easing Treasury yields and progress on Iran‑US peace discussions lifted corporate confidence and demand for cyclically exposed manufacturers. This macro‑driven sentiment shift comes shortly after concerns about Jabil’s valuation and recent insider share sales, highlighting a tension between optimism and perceived risk. Next, we’ll examine how improving risk appetite tied to lower Treasury yields may influence Jabil’s...

Wondering if Wells Fargo at around US$76 per share still offers value, or if most of the opportunity has already been priced in? This article breaks that question down using several valuation tools. The stock is close to its recent last close of US$76.11, with a modest 0.4% gain over the past week but a decline of 5.5% over the past month and a larger fall of 20.1% year to date, set against a 5.5% return over the last year and 106.0% over three years. Recent coverage has focused on Wells...

If you are wondering whether Main Street Capital at US$51.12 is offering good value today, the key is to separate the headline share price from what the business may actually be worth. The stock is roughly flat over the last 7 days, has fallen about 5.2% over the last 30 days, is down 17.2% year to date, yet is still up 64.1% over 3 years and 80.2% over 5 years, a mix that can leave investors questioning what the current price really reflects. Recent attention on the broader capital markets...

Semtech (SMTC) opened Q1 2027 with revenue of about US$291 million, basic EPS of roughly US$0.29 and net income of around US$26.6 million, providing a clear snapshot of its latest quarterly performance. The company reported revenue of about US$251.1 million in Q1 2026 and roughly US$291 million in Q1 2027, while basic EPS moved from about US$0.22 to roughly US$0.29 over the same period. This offers investors a direct view of how the top and bottom line compare year on year. Overall, margins...

MediWound (NasdaqGM:MDWD) opened Q1 2026 with revenue of US$1.5 million and a basic EPS loss of US$0.23, alongside a trailing twelve month basic EPS loss of US$2.19 on revenue of US$14.5 million. Over recent quarters the company has seen quarterly revenue move from US$3.96 million in Q1 2025 to US$5.71 million in Q2, US$5.43 million in Q3 and US$1.87 million in Q4. Quarterly basic EPS losses ranged between US$0.07 and US$1.23, setting the backdrop for the latest numbers and the growth...

Stock move and recent performance context A10 Networks (ATEN) has recently attracted investor attention after its share price movement, prompting a closer look at how the stock has been trading over the past month and past 3 months. See our latest analysis for A10 Networks. A10 Networks' recent momentum has been strong, with a 30 day share price return of 5.27% and a 90 day share price return of 51.35%. The 1 year total shareholder return of 72.12% and 5 year total shareholder return of 221%...

DocuSign (DOCU) stock is back in focus after the company used its Momentum conference to showcase Iris, a new AI engine that sits at the center of its Intelligent Agreement Management platform. See our latest analysis for DocuSign. Despite the product buzz around Iris and Intelligent Agreement Management, the stock has been under pressure, with the share price at US$48.43, a year-to-date share price decline of 25.32%, and a 1-year total shareholder return decline of 43.57%. However, the...

What recent performance suggests about Gartner (IT) With no single headline event driving attention today, Gartner (IT) is drawing interest as investors weigh its recent share performance against fundamentals such as revenue of US$6.47b and net income of US$740.64m. See our latest analysis for Gartner. At a share price of US$159.97, Gartner has seen a 7.52% 1 month share price return and a 1.32% 1 day move. However, longer term total shareholder returns over 1, 3 and 5 years have been weak,...

Walmart (WMT) is back in focus after solid first quarter results, with revenue of US$177.8b and net income of US$5.3b, followed by cautious guidance that coincided with a sharp pullback in the stock. See our latest analysis for Walmart. That cautious first quarter outlook and worries about fuel costs have hit sentiment hard, with the share price down 9.4% over the past week and 7.1% over the past month, even though the 1 year total shareholder return is 22.9% and the 5 year total shareholder...

A. O. Smith Corporation recently announced that Carrie L. Anderson will become executive vice president and chief financial officer on July 1, 2026, succeeding long‑time finance leader Charles T. Lauber, who will stay through September 30, 2026 to support a smooth transition. Anderson’s combination of engineering and financial leadership experience across global industrial, manufacturing and technology companies may influence how A. O. Smith approaches capital allocation, innovation funding...

Zoom Communications (ZM) recently completed its corporate rebrand from Zoom Video Communications, signaling a broader focus on its AI first open work platform and multi product ecosystem beyond core video meetings. See our latest analysis for Zoom Communications. At a share price of US$99.96, Zoom’s recent momentum has picked up, with a 30 day share price return of 10.05% and a 90 day gain of 32.33%. The 1 year total shareholder return of 25.47% contrasts with a 5 year total shareholder...

Event overview and recent share performance Berkshire Hathaway (BRK.A) is back in focus after recent trading left the stock down slightly over the past week and roughly flat over the past month, prompting investors to reassess its long term role in portfolios. See our latest analysis for Berkshire Hathaway. Stepping back, Berkshire Hathaway’s share price return is down 3.4% year to date and down 4.6% over the past 90 days, while its 3 year total shareholder return of 47.3% points to stronger...

Fulton Financial (FULT) has drawn investor attention after recent share price moves, with the stock closing at US$21.60. Short term returns have been mixed, while longer term performance remains meaningfully positive. See our latest analysis for Fulton Financial. Recent trading has been relatively muted, with the share price slipping 0.8% over the last day and 1.5% over the past month. The year to date share price return of 10.9% sits alongside a 1 year total shareholder return of 30.3%,...

If you are wondering whether QUALCOMM at US$233.40 still offers value or if you may be arriving late to the story, this article breaks down what the current price may imply. The stock has posted returns of 15.3% over the past 7 days, 55.3% over 30 days, 34.9% year to date, 61.8% over 1 year, 118.8% over 3 years and 93.6% over 5 years, which is likely to influence how investors think about both upside and risk. Recent coverage has focused on QUALCOMM's position in semiconductors and wireless...

What Lazard’s board changes mean for shareholders Lazard (LAZ) is moving from a staggered, multi year board structure to annual director elections. This governance shift could change how quickly shareholders influence the company after a mixed start to the year. See our latest analysis for Lazard. The governance change comes after a mixed few months for the stock, with the share price down 9.02% over 90 days and 3.22% year to date. However, the 3 year total shareholder return is 92.91%,...

Earlier in May 2026, Recursion Pharmaceuticals reported first-quarter revenue of US$6.5 million, a reduced net loss, and confirmed that its cash and cash equivalents are expected to support operations into early 2028 while advancing multiple clinical programs, including REC-4881, REC-1245, and REC-4539. A particularly interesting development is the Phase 2 efficacy signal for REC-4881 in familial adenomatous polyposis, which underscores how Recursion’s AI-native discovery platform is...

Enterprise Products Partners at a glance Enterprise Products Partners (EPD) remains in focus for income oriented investors, with the stock recently closing at $37.99 and the partnership generating revenue of $51.57b and net income of $5.84b. See our latest analysis for Enterprise Products Partners. Recent trading has been a little softer, with the share price down 3.6% over the past week, but the 18.1% year to date share price return and 5 year total shareholder return of 123.9% point to...

Wondering if Astec Industries at about US$51 per share is offering fair value right now, or if the recent price puts you at risk of overpaying? The stock is up 4.9% over the last 7 days and 14.4% year to date, although it is down 13.1% over the past month, with a 31.0% return over the last year and 44.0% over three years, while the five-year return shows a decline of 20.8%. Recent headlines around infrastructure spending, construction activity and heavy equipment demand have kept attention...

Insulet (NasdaqGS:PODD) issued a voluntary recall and medical device correction for certain Omnipod insulin Pods due to a manufacturing defect that can cause insulin under delivery. The action affects roughly 7 million Pods globally across the Omnipod 5, DASH, and Eros product lines. Insulet has received multiple reports of serious adverse events, including at least 24 severe cases requiring hospitalization, but no fatalities. The company is replacing affected Pods at no cost and does not...

Earlier this month, Quanta Services appointed Joseph Kim to its board, authorized a US$1.00 billion share repurchase program, and affirmed a quarterly dividend of US$0.11 per share payable on July 13, 2026. These moves combine fresh boardroom expertise in supply chain and logistics with capital returns that underscore management’s current priorities around buybacks and steady income. Next, we’ll examine how the new US$1.00 billion buyback authorization could influence Quanta’s existing...

Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin-4 antibody‑drug conjugate CRB-701, showing robust activity and manageable safety in HPV‑driven oropharyngeal and cervical cancers, with plans to present the results at the ASCO 2026 meeting and to launch registrational trials in both indications. An interesting development is the FDA’s broad alignment on registrational trial designs targeting accelerated approval in second‑line oropharyngeal squamous cell carcinoma and...

Earlier this month, Argan Inc. reported fourth-quarter earnings of US$3.47 per share on revenue of US$262.1 million, exceeding Wall Street expectations. The earnings beat has prompted analysts to revisit their assumptions on Argan's earnings power and project execution ahead of its upcoming first-quarter 2026 results on June 4. Next, we'll examine how this earnings outperformance and raised analyst forecasts may reshape Argan's existing investment narrative around backlog and margins. We've...

Why Visa (V) is back on investors’ radar Visa (V) has attracted fresh attention after a recent shift in its share performance, with the stock up about 6% over the past month following earlier year to date and 1 year declines. See our latest analysis for Visa. Visa’s recent 5.8% 30 day share price return contrasts with a year to date decline of 5.45% and a 1 year total shareholder return that is down 8.21%, while the 3 year total shareholder return of 51.64% points to stronger longer term...